{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:14:16Z","timestamp":1791486856448,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","award":["016737004"],"award-info":[{"award-number":["016737004"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","award":["016634006"],"award-info":[{"award-number":["016634006"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","award":["R016334002"],"award-info":[{"award-number":["R016334002"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["R016520008"],"award-info":[{"award-number":["R016520008"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006215","name":"National Performance Network","doi-asserted-by":"publisher","award":["IRN5801PHDW03"],"award-info":[{"award-number":["IRN5801PHDW03"]}],"id":[{"id":"10.13039\/100006215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N34E670096"],"award-info":[{"award-number":["N34E670096"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N35E660102"],"award-info":[{"award-number":["N35E660102"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118806","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:08:24Z","timestamp":1763701704000},"page":"118806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Next-generation CAR T cells targeting integrin \u03b1v\u03b26 and PD-L1 to enhance immunotherapy for cholangiocarcinoma"],"prefix":"10.1016","volume":"193","author":[{"given":"Chalermchai","family":"Somboonpatarakun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaporn","family":"Phanthaphol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwanpirom","family":"Suwanchiwasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7664-2482","authenticated-orcid":false,"given":"Boonyanuch","family":"Ramwarungkura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-3000","authenticated-orcid":false,"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2025.118806_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.6004\/jnccn.2017.7056","article-title":"Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the united states","volume":"16","author":"Mukkamalla","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"5","key":"10.1016\/j.biopha.2025.118806_bib2","first-page":"1159","article-title":"Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on east and south-eastern asia","volume":"11","author":"Shin","year":"2010","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2025.118806_bib3","doi-asserted-by":"crossref","unstructured":"E.J. Koay, B.C. Odisio, M. Javle, J.-N. Vauthey, C.H. Crane, Nutrition, Management of unresectable intrahepatic cholangiocarcinoma: How do we decide among the various liver-directed treatments?, 2017 6(2), 2017: 105-116.","DOI":"10.21037\/hbsn.2017.01.16"},{"issue":"5-6","key":"10.1016\/j.biopha.2025.118806_bib4","first-page":"155","article-title":"Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis","volume":"4","author":"Eckmann","year":"2011","journal-title":"Gastrointest. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2025.118806_bib5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.biopha.2025.118806_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in car t cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.biopha.2025.118806_bib7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor t cells in refractory b-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.biopha.2025.118806_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory b-cell lymphomas with car t-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.biopha.2025.118806_bib9","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-bcma car t-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118806_bib10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s13277-015-4743-x","article-title":"Immunotherapy of biliary tract cancer","volume":"37","author":"Chai","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.biopha.2025.118806_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"Car t cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118806_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist car t cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118806_bib13","first-page":"1671","article-title":"Programmed death-ligand 1 (pd-l1) expression associated with a high neutrophil\/lymphocyte ratio in cholangiocarcinoma","volume":"18","author":"Sangkhamanon","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2025.118806_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1119168","article-title":"Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis","volume":"14","author":"Xian","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118806_bib15","doi-asserted-by":"crossref","first-page":"1204486","DOI":"10.3389\/fonc.2023.1204486","article-title":"Comparison analysis of pd-1\/pd-l1 inhibitors plus lenvatinib or gemcitabine\/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma","volume":"13","author":"Huang","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118806_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12967-025-06453-y","article-title":"Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor t cells targeting integrin \u03b1v\u03b26 and secreting anti-pd-l1 scfv","volume":"23","author":"Phanthaphol","year":"2025","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2025.118806_bib17","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific t-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118806_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A cd19\/cd3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.biopha.2025.118806_bib19","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2025.118806_bib20","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted bites complement car t cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2025.118806_bib21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"Car-t cells secreting bites circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118806_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118806_bib23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.omtm.2021.04.007","article-title":"The impact of lentiviral vector genome size and producer cell genomic to gag-pol mrna ratios on packaging efficiency and titre","volume":"21","author":"Sweeney","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"10","key":"10.1016\/j.biopha.2025.118806_bib24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory t cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118806_bib25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4062\/biomolther.2022.015","article-title":"Bispecific antibody-bound t cells as a novel anticancer immunotherapy","volume":"30","author":"Cho","year":"2022","journal-title":"Biomol. Ther. (Seoul. )"},{"issue":"23","key":"10.1016\/j.biopha.2025.118806_bib26","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor t cells secreting anti-pd-l1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2025.118806_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific t cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"3-4","key":"10.1016\/j.biopha.2025.118806_bib28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cyto.2006.11.008","article-title":"Induction of granzyme b and t cell cytotoxic capacity by il-2 or il-15 without antigens: Multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal","volume":"36","author":"Tamang","year":"2006","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118806_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.biopha.2025.118806_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific t cell engager (bite\u00ae) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PLOS ONE"},{"issue":"49","key":"10.1016\/j.biopha.2025.118806_bib31","doi-asserted-by":"crossref","first-page":"25656","DOI":"10.1074\/jbc.M116.753145","article-title":"Interferon-\u03b3 promotes antibody-mediated fratricide of acute myeloid leukemia cells","volume":"291","author":"Fatehchand","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2025.118806_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:21:43Z","timestamp":1778631703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"alternative-id":["S0753332225010005"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118806","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation CAR T cells targeting integrin \u03b1v\u03b26 and PD-L1 to enhance immunotherapy for cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118806"}}